Estradiol benzoate/hydroxyprogesterone caproate

Estradiol benzoate /
hydroxyprogesterone caproate
Combination of
Estradiol benzoate Estrogen
Hydroxyprogesterone caproate Progestogen
Clinical data
Trade names Primosiston, others
Synonyms EB/OHPC
Routes of
administration		 Intramuscular injection
ATC code
Identifiers
CAS Number
PubChem CID
PubChem SID
KEGG

Estradiol benzoate/hydroxyprogesterone caproate (EB/OHPC), sold under the brand name Primosiston among others, is a combined estrogen and progestogen medication which is used to treat gynecological disorders and habitual abortion.[1][2][3][4][5] It contains estradiol benzoate (EB), an estrogen, and hydroxyprogesterone caproate (OHPC), a progestin.[1][2][3][4][5] The medication is given by injection into muscle.[1][2][3][4][5]

Medical uses

EB/OHPC is used in the treatment of gynecological disorders such as menstrual disorders (e.g., amenorrhea, dysfunctional uterine bleeding) and premenstrual syndrome, habitual abortion (threatened miscarriage), and for other indications.[1][2][3][4]

Available forms

EB/OHPC is available in the form of ampoules of oil solutions containing 10 mg estradiol benzoate (EB) and 125 to 250 mg hydroxyprogesterone caproate (OHPC).[1][2][3][4][5]

Society and culture

Brand names

EB/OHPC has been marketed under brand names including Dos Dias N, Lutes, Ostrolut, Primosiston (or Primosiston Inj. / Injection), Primosiston Fuerte, and Syngynon.[6][7][8]

Availability

EB/OHPC has been mostly discontinued and hence is mostly no longer available.[6][7][8] It remains marketed under the brand names Primosiston in Ecuador and Peru, Dos Dias N in Argentina, and Lutes in Japan.[6][7][8] It was previously marketed under the brand names Ostrolut in Austria; Primosiston (or Primosiston Inj. / Injection) (Schering)[1][2][4] in Argentina, Germany, Mexico, Switzerland, and Venezuela; Primosiston Fuerte in Spain; and Syngynon in Germany, but these formulations have all been discontinued and hence are no longer available in these countries.[6][7][8]

See also

References

  1. 1 2 3 4 5 6 Freimut A. Leidenberger (17 April 2013). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. pp. 533–. ISBN 978-3-662-08110-5.
  2. 1 2 3 4 5 6 Karl Knörr; Fritz K. Beller; Christian Lauritzen (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 255–. ISBN 978-3-662-00942-0.
  3. 1 2 3 4 5 Heinrich Kahr (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 22–. ISBN 978-3-7091-5694-0.
  4. 1 2 3 4 5 6 Walther Kern; H. Auterhoff; F. Neuwald; W. Schmid (9 March 2013). Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte und Medizinalbeamte. Springer-Verlag. pp. 1163–. ISBN 978-3-642-49759-9.
  5. 1 2 3 4 Die Gestagene. Springer-Verlag. 27 November 2013. pp. 1045–. ISBN 978-3-642-99941-3.
  6. 1 2 3 4 https://www.drugs.com/international/hydroxyprogesterone.html
  7. 1 2 3 4 Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2082. ISBN 978-0-85369-840-1.
  8. 1 2 3 4 http://www.micromedexsolutions.com/micromedex2/librarian/


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.